Leland Johnson

The Discovery of <i>N</i>-(1-Methyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1<i>H</i>-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration

Christopher M. Adams, Karen Anderson, Gerald D. Artman et al. · Journal of Medicinal Chemistry · 2018 · 36 citations · Full text

Ocular Disease, Choroidal Neovascularization, Pharmacotherapy +17

Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration

Erik L. Meredith, Nello Mainolfi, Stephen Poor et al. · Journal of Medicinal Chemistry · 2015 · 29 citations · Full text

Translational Medicine, Ocular Disease, Ophthalmology +13

A Reliable Synthesis of 3-Amino-5-Alkyl and 5-Amino-3-Alkyl Isoxazoles

Nello Mainolfi, Leland Johnson, James J. Powers et al. · Synthesis · 2012 · 21 citations

Engineering, Reliable Procedure, Organic Chemistry +9